Latest Us Market Expansion News

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

Resolution Minerals has announced a significant gold discovery at its Golden Gate North Prospect, marking a pivotal shift from exploration to development. The company also advances its critical minerals strategy with key acquisitions and a $25 million capital raise.

GCM Corporation’s latest quarterly report confirms its VHD thermal management technology outperforms copper and aluminium, while commercial and US listing plans gain momentum.

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

RMA Global Limited has rebranded RateMyAgent to Renowned, integrating Curated Social to enhance its real estate marketing platform. The company’s strategic pivot in the US is paying off with record brokerage deals and strong revenue growth.

HyTerra Limited has unveiled a comprehensive strategic plan to commercialise its Nemaha Project in Kansas, backed by new leadership and a key US technology partnership. The company is advancing towards production testing in 2026 amid promising hydrogen and helium discoveries.

BetMakers Technology Group reported a robust Q2 FY26 with positive adjusted EBITDA and significant contract wins poised to fuel growth in the second half of the year.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.